Trial Profile
A Phase 2 Trial of Fractionated Gemtuzumab Ozogamicin to Eradicate Measurable Residual Disease in Acute Myeloid Leukemia Patients (GO for MRD)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- Acronyms GO for MRD
- 23 Mar 2023 Planned End Date changed from 1 Jun 2024 to 31 Dec 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2024.
- 19 May 2021 Planned End Date changed from 15 Aug 2021 to 1 Jun 2024.